Table 3.
Comparison of the study outcomes in Favipiravir and Lopinavir/Ritonavir treatment regimens.
| Modified ITT population |
Per-protocol population |
|||||
|---|---|---|---|---|---|---|
| Favipiravir(N = 190) | Lopinavir/Ritonavir (N = 183) | Total (N = 373) | Favipiravir(N = 153) | Lopinavir/Ritonavir (N = 147) | Total (N = 300) | |
| In-hospital mortality - no. (%) | 26 (13.7) | 21 (11.5) | 47 (12.6) Χ2 = 0.41; p = 0.52 | 22 (14.4) | 17 (11.6) | 39 (13) Χ2 = 0.53; p = 0.47 |
| Intubation - no. (%) | 27 (14.2) | 17 (9.3) | 44 (11.8) Χ2 = 2.17; p = 0.14 | 23 (15.0) | 13 (8.8) | 36 (12) Χ2 = 2.72; p = 0.1 |
| ICU admission - no. (%) | 31 (16.3) | 25 (13.7) | 56 (15.0) Χ2 = 0.51; p = 0.47 | 26 (17.0) | 18 (12.2) | 44 (14.7) Χ2 = 1.35; p = 0.25 |
| Median length of hospital stay - days (IQR)a | 7 (4–9); n = 153 | 6 (4–10); n = 150 | 6 (4–10); n = 303 Mann-Whitney U test: p = 0.85 | 6 (4–9); n = 124 | 6 (4–9); n = 122 | 6 (4–9); n = 246 Mann-Whitney U test: p = 0.92 |
| Median survival time till clinical recovery - days (IQRb) | 6 (4–10); n = 185 | 6 (4–10); n = 182 | Log-rank Χ2 = 0.38; p = 0.54 | 6 (4–9); n = 150 | 5 (3–9); n = 147 | Log-rank Χ2 = 0.38; p = 0.54 |
a
patients discharged against medical advice were excluded
b
Inter Quartile Range